|
LIVE WEBINAR: Tuesday, July 11, 2023, 5:00 PM – 6:00 PM Eastern Time
Inside the Issue: Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic SyndromesA CME/MOC-Accredited Live WebinarJoin us on Tuesday, July 11th for this CME/MOC-accredited webinar Faculty
Guillermo Garcia-Manero, MD McCredie Professor of Medicine Chief, Section of MDS Vice Chair, Department of Leukemia The University of Texas MD Anderson Cancer Center Houston, Texas
David Sallman, MD
Associate Member Malignant Hematology Moffitt Cancer Center Tampa, Florida Moderator Neil Love, MD Research To Practice Miami, Florida Tuesday, July 11, 2023 Topics to Be Discussed
Target Audience
CE Credit FACULTY — Dr Garcia-Manero has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities: Dr Sallman — Advisory Committee: AvenCell, bluebird bio, Bristol Myers Squibb, Intellia Therapeutics, Jasper Therapeutics Inc, Kite, A Gilead Company, Magenta Therapeutics, Nkarta Inc, Novartis, Servier Pharmaceuticals LLC, Shattuck Labs, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, Affimed GmbH, Gilead Sciences Inc, Incyte Corporation, Molecular Partners, Precigen Inc, Takeda Pharmaceuticals USA Inc, Zentalis Pharmaceuticals; Contracted Research: Aprea Therapeutics, Jazz Pharmaceuticals Inc; Nonrelevant Financial Relationship: Intellisphere Oncology Specialty Group.SURVEY PARTICIPANTS — Uma Borate, MD, MS — Consulting Agreements: AbbVie Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Gilead Sciences Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: AbbVie Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Novartis; Data and Safety Monitoring Board/Committee: Takeda Pharmaceuticals USA Inc. Andrew M Brunner, MD — Consulting Agreements: Acceleron Pharma, Agios Pharmaceuticals Inc, Bristol Myers Squibb, Gilead Sciences Inc, Keros Therapeutics, Novartis, Rigel Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc. Amy E DeZern, MD, MHS — Consulting Agreements: Apellis, Caribou Biosciences, Bristol Myers Squibb, Geron, Novartis, Regeneron Pharmaceuticals Inc, Sobi; Data and Safety Monitoring Board/Committee: Geron. Richard M Stone, MD — Advisory Board: AbbVie Inc, Actinium Pharmaceuticals Inc, Amgen Inc, Arog Pharmaceuticals Inc, AvenCell, Boston Pharmaceuticals, Bristol Myers Squibb, Celularity, CTI BioPharma Corp, Genentech, a member of the Roche Group, GSK, Hemavant, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kura Oncology, Lava Therapeutics, Ligand Pharmaceuticals Incorporated, Novartis, Syros Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; AML Expert Council: GSK; Data and Safety Monitoring Board/Committee: Aptevo Therapeutics, Epizyme Inc, Syntrix Pharmaceuticals, Takeda Pharmaceuticals USA Inc; Focus Group: BerGenBio ASA; Grand Rounds: Jazz Pharmaceuticals Inc; Steering Committee: AbbVie Inc. Eunice S Wang, MD — Advisory Committee and Consulting Agreements: AbbVie Inc, Bristol Myers Squibb, CTI BioPharma Corp, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GSK, Johnson & Johnson Pharmaceuticals, Kite, A Gilead Company, Kura Oncology, Novartis, Rigel Pharmaceuticals Inc, SELLAS Life Sciences, Sumitomo Dainippon Pharma Oncology Inc; Data and Safety Monitoring Board/Committee: AbbVie Inc, Gilead Sciences Inc; Speakers Bureau: Astellas, Kura Oncology, Pfizer Inc. MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc. Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupporterThis activity is supported by an educational grant from Gilead Sciences Inc. |